Home › Psychology Rejection › NCT07079735
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
RecruitingPhase 2/3
VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included. Exclusion Criteria: History of or suspected CMV disease within 6 months prior is excluded.
About the study
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
What is being tested
- Letermovir (drug)
- Valganciclovir (drug)
Sponsor: Columbia University · Participants: 150 · Started: Sep 12, 2025
Contact the study team
- Afsana Rahman, MD · Phone: 2123054600
Official record on ClinicalTrials.gov — NCT07079735
Locations in the U.S.
| New York | Columbia University/NYP Milstein Hospital, New York NYP-Weill Cornell, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.